home / stock / aim / aim news

AIM News and Press, AIM ImmunoTech Inc. From 07/21/22

Stock Information
Company Name: AIM ImmunoTech Inc.
Stock Symbol: AIM
Market: NYSE
Website: aimimmuno.com
Menu
AIM AIM Quote AIM Short AIM News AIM Articles AIM Message Board
Get AIM Alerts

News, Short Squeeze, Breakout and More Instantly...
AIM - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off Thursday with an overview of the biggest pre-market stock movers traders need to know about! We’ve got bankruptcy talk, takeover rumors, updated out...
AIM - AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data

Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC) New patient data provide further validation for advancing the development of...

AIM - AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid

Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions – Including a Potential Hostile Takeover of the Company – and Prevent Group from Continued Violations of Federal Securities Laws and SEC and Florida Injunctions Complaint Highlights...

AIM - AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series

OCALA, Fla., July 14, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral ...
AIM - AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing

OCALA, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral ...

AIM - AIM ImmunoTech receives patent coverage in Netherlands for potential COVID-19 treatment

AIM ImmunoTech (NYSE:AIM) said on Monday the Netherlands Patent Office had issued a patent covering its drug Ampligen (rintatolimod) and other developed dsRNA products for use in the prevention or treatment of COVID-19. The base patent term extends until 2041. The company's drug ...

AIM - AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or Prevention

OCALA, Fla., June 13, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral ...
AIM - AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference

OCALA, Fla., May 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral d...

AIM - AIM working on new drug application for Ampligen mid-stage study to treat long COVID

AIM ImmunoTech (NYSE:AIM) on Wednesday said it was working toward filing an investigational new drug application with the U.S. Food and Drug Administration for a phase 2 study of its investigational drug Ampligen for the treatment of post-COVID conditions. Post-COVID conditions, or long COVID...

AIM - AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program

OCALA, Fla., May 18, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral d...
Previous 10 Next 10